
Mateja Škamperle1, Katja Seme1, Maja M. Lunar1, Polona J. Maver1, Janez Tomažič2, Tomaz D. Vovko2, Blaž Pečavar2, Mojca Matičič2, Mario Poljak1✉

Abstract

Introduction: Since the introduction of highly active antiretroviral therapy (HAART), which has prolonged the survival of HIV-infected individuals (1), and significant overlap in the transmission pathways of hepatitis C virus (HCV) and HIV, chronic hepatitis C has become one of the leading causes of non–AIDS-related morbidity and mortality in patients with HIV infection (2). Coinfection with HCV occurs in 25% of HIV-infected individuals, although rates vary widely in different patient populations and are the highest among intravenous drug users (IVDU) and men who have sex with men (MSM) (3–5).

Methods and results: The presence of HCV infection was tested in 579/639 (90.6%) patients that were confirmed as HIV-positive in Slovenia by the end of 2013. Among them, 7.6% (44/579) of HIV-infected individuals were anti-HCV-positive, and 33/44 (75%) anti-HCV–positive patients were also HCV RNA–positive. HCV genotype 1 was most prevalent among HIV-infected patients (68%), followed by genotype 3 (20%), genotype 4 (8%), and genotype 2 (4%). Anti-HCV positivity was significantly higher in those that acquired HIV by the parenteral route (91.8%) than in those that acquired HIV by the sexual route (2.8%).

Discussion: Slovenia remains among the countries with the lowest prevalence of HCV infection in HIV-infected individuals. Because the burden of HIV among men who have sex with men in Slovenia is disproportionately high and increasing rapidly, the current favorable situation could change quickly and should be therefore monitored regularly.

Received: 24 April 2014 | Returned for modification: 8 May 2014 | Accepted: 30 May 2014

Introduction

Due to the use of highly active antiretroviral therapy (HAART), which has prolonged the survival of HIV-infected individuals (1), and significant overlap in the transmission pathways of hepatitis C virus (HCV) and HIV, chronic hepatitis C has become one of the leading causes of non–AIDS-related morbidity and mortality in patients with HIV infection (2). Coinfection with HCV occurs in 25% of HIV-infected individuals, although rates vary widely in different patient populations and are the highest among intravenous drug users (IVDU) and men who have sex with men (MSM) (3–5).

Slovenia is a small central European country with a relatively low prevalence but increasing incidence of HIV infection (6). The burden of HIV among MSM in Slovenia is disproportionately high and increasing quickly, whereas it is very low among IVDU (7). In our previous nationwide studies published in 2002 and 2009, we found a very low prevalence of HCV infection among Slovenian HIV-infected individuals (14.5% and 10.7%, respectively) (8, 9). Because several developed countries have recently faced a dramatic increase in the incidence of acute hepatitis C among HIV-infected MSM (10–12), here we have updated the HCV infection prevalence data in Slovenian HIV-infected individuals.

Methods

For the purpose of this study, data collected for the most recent published study on the topic (9) were updated with those obtained from 230 Slovenian individuals that were newly diagnosed as HIV-positive between 1 January 2009 and 31 December 2013. Overall, 579 of 639 (90.6%) patients that were confirmed as HIV-positive by the end of 2013 were tested for the presence of HCV infection.

The presence of anti-HCV was determined using the Ortho HCV Assay (Ortho Diagnostic Systems). Anti-HCV reactive specimens were confirmed by the Inno-Lia HCV Ab III Update Assay (Innogenetics, Zwijndrecht, Belgium). HCV RNA was detected using several generations of commercial HCV RNA viral load assays.

Results

Among 579 individuals included in the study, 505 (87.2%) were men and 74 (12.8%) women, and mean age at the time of HIV diagnosis was 37.4 years (range 0–76 years). The sexual transmission route was predominant (483.5/579, 83.5%), followed by the parenteral HIV transmission route (24.5/579, 4.2%), mother-to-child transmission (6/579, 1.0%), and transmission by human bite (1/579, 0.2%) (13). The route of transmission was unknown for 64/579 (11.1%) HIV-infected individuals. MSM accounted for 62.9% of all HIV-infected individuals included in the study.

The presence of anti-HCV antibodies was detected in 7.6% (44/579) HIV-infected individuals. Thirty-three out of 44 (75%) seropositive patients were also HCV RNA–positive. HCV RNA was not detected in any of the 535 anti-HCV–negative HIV-infected individuals. HCV genotype 1 was most prevalent among HIV-infected patients (68%), followed by genotype 3 (20%), genotype 4 (8%), and genotype 2 (4%).

Anti-HCV positivity was significantly higher in those that acquired HIV by the parenteral route (91.8%) than in those that acquired HIV by the sexual route (2.8%).

Discussion

In Slovenia, screening for HCV infection has been the standard of
medical care in management of HIV-infected individuals since 2001. The study performed in 2002 demonstrated a low prevalence (14.5%) of HCV infection among Slovenian HIV-infected individuals (8). In a follow-up study performed on 87% of the entire population of Slovenian HIV-infected individuals identified by the end of 2008, the prevalence of HCV infection decreased to 10.7% (9). In the present study, which included 90.6% of the entire population of Slovenian HIV-infected individuals identified by the end of 2013, a further decrease in the prevalence of HCV infection was observed and reached only 7.6%. The predominance of HCV genotype 1 among HIV-infected individuals followed by HCV genotype 3 remained unchanged and is in agreement with the HCV genotype distribution in the general population of HCV-positive individuals in Slovenia (14). As noticed in our previous studies, the HCV infection in those that acquired HIV by the parenteral route predominated over individuals that acquired HIV by the sexual route. There are probably two main reasons for the unusual relatively low prevalence of HCV infection among Slovenian HIV-infected individuals. Namely, the IVDU population in Slovenia has so far largely been spared from HCV infection and it also seems that the MSM population in Slovenia has so far largely been spared from HCV infection. However, the situation may change in the near future because we recently detected a few acute hepatitis C cases among HIV-infected MSMs.

Conclusion

Slovenia remains among the countries with the lowest prevalence of HCV infection among HIV-infected individuals. Because the burden of HIV among MSMs in Slovenia is disproportionately high and increasing rapidly, the current favorable situation could quickly change and should therefore be monitored regularly.

References